The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

LS-117636     cyclohexane-1,2-diamine; 7,7...

Synonyms: AC1L535E, 113427-19-3, Bis-neodecanoato-dach-Pt(II)
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Aroplatin

  • CONCLUSION: Intrapleural L-NDDP therapy in this patient population is feasible with significant but manageable toxicity [1].
  • PURPOSE: To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma [1].
  • Free NDDP administered i.v. was inactive against liver metastases of M5076 reticulosarcoma (%T/C 102) while L-NDDP showed significant activity (%T/C 140) [2].
  • PATIENTS AND METHODS: Thirty-three patients with malignant pleural mesothelioma and free-flowing pleural effusions received intrapleural L-NDDP once every 3 weeks at a dose of 450 mg/m2 [1].
  • When injected i.v., only L-NDDP showed significant activity against L1210 leukemia i.v. (percentage of T/C: 186%) [3].
 

High impact information on Aroplatin

 

Chemical compound and disease context of Aroplatin

 

Biological context of Aroplatin

  • In dogs, the maximum tolerated dose (MTD) of L-NDDP given i.v. over a period of 45-60 min was 150 mg/m2 [6].
  • In addition, significant differences in pharmacokinetic parameters were observed between drug-treatment groups that were independent of the route of administration: the serum Pt area under the concentration-time curve (AUC) was higher and the volume of distribution at steady state (Vdss) was lower in rats receiving L-NDDP [7].
  • The pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) and cisplatin (CDDP) were studied after i.v. and i.p. administration of an equimolar dose (11 and 5 mg/kg for L-NDDP and CDDP, respectively) in the rat [7].
  • In A2780 cells, both drugs were markedly effective in inducing DNA fragmentation, whereas in A2780/PDD cells, only L-NDDP produced significant DNA fragmentation, in good correlation with the observed cytotoxicity [8].
  • The degradation/activation kinetics of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diamminocyclohexane platinum (II) [L-NDDP] at different conditions of pH, and temperature is presented [9].
 

Anatomical context of Aroplatin

  • Following the i.v. injection of L-NDDP, hepatocytes contained up to 6-fold higher platinum concentrations than KC [4].
  • CONCLUSIONS: Peritoneal cavity exposure to L-NDDP is prolonged, and systemic absorption is limited, yielding a high peritoneal/plasmatic ratio [10].
  • Pt levels measured at 6 h in the peritoneal fluid, peritoneal tissue, and intestine of rats receiving i.p. L-NDDP were higher than those observed in rats receiving either i.v. L-NDDP or CDDP by either route [7].
  • In rabbits bearing liver tumors of VX2 carcinoma, i.v. administration of L-NDDP resulted in 2- to 20-fold higher Pt levels in all tissues (including VX2 tumors) except the brain and peripheral nerve than in animals treated with an equimolar dose of cisplatin [11].
  • Bone marrow hypoplasia was detected in some cats that received higher doses (cumulative dosages of 300 or 400 mg of L-NDDP/m2) [12].
 

Gene context of Aroplatin

 

Analytical, diagnostic and therapeutic context of Aroplatin

References

  1. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. Lu, C., Perez-Soler, R., Piperdi, B., Walsh, G.L., Swisher, S.G., Smythe, W.R., Shin, H.J., Ro, J.Y., Feng, L., Truong, M., Yalamanchili, A., Lopez-Berestein, G., Hong, W.K., Khokhar, A.R., Shin, D.M. J. Clin. Oncol. (2005) [Pubmed]
  2. Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. Perez-Soler, R., Yang, L.Y., Drewinko, B., Lauterzstain, J., Khokhar, A.R. Cancer Res. (1988) [Pubmed]
  3. Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Khokhar, A.R., al-Baker, S., Krakoff, I.H., Perez-Soler, R. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  4. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes. Lautersztain, J., Perez-Soler, R., Turpin, J., Khokhar, A.R., Siddik, Z.H., Schmidt, K., Lopez-Berestein, G. Cancer Res. (1988) [Pubmed]
  5. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Dragovich, T., Mendelson, D., Kurtin, S., Richardson, K., Von Hoff, D., Hoos, A. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  6. Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Perez-Soler, R., Lautersztain, J., Stephens, L.C., Wright, K., Khokhar, A.R. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  7. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Vadiei, K., Siddik, Z.H., Khokhar, A.R., al-Baker, S., Sampedro, F., Perez-Soler, R. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  8. Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Han, I., Ling, Y.H., Khokhar, A.R., Perez-Soler, R. Anticancer Res. (1994) [Pubmed]
  9. Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent. Maclean, D.S., Khokhar, A.R., Tyle, P., Perez-Soler, R. Journal of microencapsulation. (2000) [Pubmed]
  10. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. Verschraegen, C.F., Kumagai, S., Davidson, R., Feig, B., Mansfield, P., Lee, S.J., Maclean, D.S., Hu, W., Khokhar, A.R., Siddik, Z.H. J. Cancer Res. Clin. Oncol. (2003) [Pubmed]
  11. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Khokhar, A.R., Wright, K., Siddik, Z.H., Perez-Soler, R. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  12. Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats. Fox, L.E., Toshach, K., Calderwood-Mays, M., Khokhar, A.R., Kubilis, P., Perez-Soler, R., MacEwen, E.G. Am. J. Vet. Res. (1999) [Pubmed]
  13. Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Kelland, L.R. J. Inorg. Biochem. (1999) [Pubmed]
 
WikiGenes - Universities